Baltimore, MD, 31 March 2014. – A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.
The newly published report shows that eye drops containing the anti-anginal drug dipyridamole (Persantin®, Cardoxin®) led to almost total disappearance of an inflamed pterygium in a 35 year old otherwise healthy woman.
Dipyridamole is a drug in use over the past 55 years to treat other disorders, but now found to have this remarkable new use.
Pterygium is a disorder in which a non-cancerous growth develops on the white conjunctiva of the eye and over time invades the cornea. In some countries it affects up to 25% of the population. As the growth spreads, patients can develop vision problems as well as significant discomfort from complications such as dry eye, inflammation, irritation, and foreign body sensation. Additionally, because of their location in the eyes, pterygia are a cause of substantial cosmetic concern for sufferers.
Until now, eye surgery has been the only curative option, aided by medications trying to lessen the disorder's symptoms. However, even after eye surgery, pterygia often recur.
The new report's lead author, Moshe Rogosnitzky, who is Co-Founder and Director of Research at the MedInsight Research Institute, discovered that administration of dipyridamole eye drops significantly reduced a pterygium and completely resolved the associated inflammation and other symptoms.
Clinical trials are now being plannedfor pterygia, pingueculae, and other common eye disorders and their complications such as dry eye and inflammation.
One particular advantage to this discovery is that dipyridamole is a widely-approved anti-thrombosis medication that has been in use for over 55 years. Its safety profile is well-established; as such, fast-track development of dipyridamole eye drops as a repurposed drug is feasible.
Moshe Rogosnitzky commented on this finding, "Pterygium and dry eye are debilitating disorders for which new safe solutions are urgently needed, and I believe dipyridamole has the potential to provide relief to sufferers of these intractable conditions.
Rogosnitzky, who specializes in finding new uses for old drugs, continued, "This is yet another example of the advantages of drug repurposing. Whereas bringing a new drug to market can take up to 17 years or more, finding a new use for an old drug with an excellent safety profile can lead to approval and availability in as little as two years."
The findings of this report and photos of the treated eye are published in Case Reports in Ophthalmology (2014; 5:pp. 98-103) on March 25, 2014.
About MedInsight® Research Institute
MedInsight® Research Institute is committed to bringing relief to those who suffer from cancer or chronic medical conditions by making doctors aware of commercially unsponsored medications, off-label uses for approved medicines, long-lost therapies and specialized tests that enable treatment to be tailored to the individual. As a U.S.-based 501(c)(3) non-profit organization, MedInsight works to bridge the widening gap between medical research and medical practice. http://www.medinsight.org
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.